IgA Nephropathy (IgAN)SWIANNCT07555301
Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
An observational study of IgA Nephropathy (IgAN), run by Waid City Hospital, Zurich at 1 site in Switzerland.
Trial summary
An observational study tracking the clinical course of patients with IgA nephropathy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- IgA Nephropathy (IgAN)
- What is being tested?
- sparsentan
- How many people
- 50 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jun 2026to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with IgA Nephropathy and therapy with sparsentan
Who may be able to join
- IgA Nephropathy, Use of Sparsentan
Who cannot join
- age < 18y
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site
Stadtspital Zurich
Zurich, Canton of Zurich, 8000
Andi Schleich, +41 44 417 21 55, Andreas.schleich@stadtspital.ch
About this study
An observational study tracking the clinical course of patients with IgA nephropathy.
Read the detailed description
The aim is to monitor the clinical progression of patients with histologically confirmed IgA nephropathy in terms of GFR and proteinuria.
- Conditions
- IgA Nephropathy (IgAN)
- Being tested
- sparsentan
- Medical subject headings
- Glomerulonephritis, IGA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sparsentanDrug
Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR
sparsentanDrug
follow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan
| Study group | Role | What they receive |
|---|---|---|
| Patients with IgA Nephropathie and a therapy with Sparsentan | Not described Receives: Drug: sparsentan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of Albuminuria
What is the impact of sparsentan on Albuminuria
Measured: 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study start1 Jun 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IgA Nephropathy (IgAN)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Waid City Hospital, Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Schleich Andreas, Waid City Hospital, Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07555301
- Sponsor's protocol ID
- WaidCH2026
- Acronym
- SWIAN
- Status last verified
- Apr 2026
- First submitted
- 21 Apr 2026
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: according to patients wishes
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
- ClinicalTrials.gov ID
- NCT07555301
- Acronym / sponsor ID
- SWIAN / WaidCH2026
- Conditions
- IgA Nephropathy (IgAN)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Waid City Hospital, ZurichUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An observational study tracking the clinical course of patients with IgA nephropathy.
Detailed description
The aim is to monitor the clinical progression of patients with histologically confirmed IgA nephropathy in terms of GFR and proteinuria.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with IgA Nephropathie and a therapy with Sparsentan | – | Drug: sparsentan |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with IgA Nephropathy and therapy with sparsentan
Key inclusion criteria (1 listed)
- IgA Nephropathy, Use of Sparsentan
Key exclusion criteria (1 listed)
- age < 18y
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sparsentanFollow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR | Drug | Patients with IgA Nephropathie and a therapy with Sparsentan |
| sparsentanfollow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan | Drug | Patients with IgA Nephropathie and a therapy with Sparsentan |
Primary outcome
Change of Albuminuria
Time frame: 36 months
What is the impact of sparsentan on Albuminuria
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: No. according to patients wishes
Related trials for IgA Nephropathy (IgAN)
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
RecruitingPhase 3
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Kidney Disease
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
RecruitingPhase 2
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
Glomerulonephritis
RecruitingPhase 3
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
IgA Nephropathy (IgAN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of IgA Nephropathy (IgAN), run by Waid City Hospital, Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andi Schleich (+41 44 416 21 55, Andreas.schleich@stadtspital.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of Albuminuria (time frame: 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.